4 reports of non-serious adverse events following rollout of Nuvaxovid COVID-19 vaccine in Singapore

SINGAPORE: There have been four reports of non-serious adverse events in the two weeks following the rollout of the Nuvaxovid COVID-19 vaccine in Singapore, said the Health Sciences Authority (HSA) on Monday (Jun 27). 

These include rash, vasculitis (inflammation of blood vessels), dizziness and chest pain. 

“These are largely consistent with what was reported in the clinical studies and are known adverse effects associated with vaccines,” HSA said.

Singapore began administering the Nuvaxovid vaccine to the public on May 18 and 2,792 doses have been administered as of May 31, said HSA in a safety update.

This is the 12th such update, covering the period since the rollout of COVID-19 vaccines on Dec 30, 2020 to May 31, 2022.

An adverse event is classified as serious when the event results in, among others, hospitalisation, a life-threatening illness or death.

HSA said it has so far not received any reports of myocarditis, an inflammatory condition of the heart, though ongoing global clinical trials of Nuvaxovid have reported a “small number” of cases. 

While the risk of myocarditis cannot be excluded, the benefits of the Nuvaxovid vaccine continue to outweigh the risks in the Singapore context, said the authority. 

HSA granted the Nuvaxovid vaccine interim authorisation in February as part of the national vaccination programme. It is available to those who have not taken their primary doses or booster shots.


See also  Nation’s brutal act to stop Christmas surge